TG THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $193M | ↑+78.0% | $23M | ↑+18.1% | 26.2% |
| 2025-09-30 | $162M | ↑+92.8% | $391M | ↑+9974.6% | 18.2% |
| 2025-06-30 | $141M | ↑+92.1% | $28M | ↑+309.8% | 24.7% |
| 2025-03-31 | $121M | ↑+90.4% | $5M | ↑+147.3% | 7.1% |
| 2024-12-31 | $108M | ↑+146.0% | $20M | — | 27.3% |
| 2024-09-30 | $84M | ↓-49.4% | $4M | ↓-96.6% | 14.8% |
| 2024-06-30 | $73M | ↑+357.0% | $7M | ↑+114.4% | 12.0% |
| 2024-03-31 | $63M | ↑+713.5% | $-11M | ↑+72.7% | -14.6% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$193M
↑+78.0% +$84M YoY
Net Income
$23M
↑+18.1% +$4M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
TGTX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyTGTX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics